OA11629A - Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake. - Google Patents

Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake. Download PDF

Info

Publication number: OA11629A
Authority: OA; OAPI
Prior art keywords: heterocycle; alkyl; quaternary; alkynyl; alkenyl
Prior art date: 1998-07-02

Application number

OA1200000365A

Other languages

English (en)

Inventor

Len F Lee

Shyamal BANERJEE

Horng-Chih Huang

Jinglin J Li

Raymond E Miller

David B Reitz

Samuel J Tremont

Original Assignee

Searle & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-02

Filing date

1999-06-29

Publication date

2004-11-10

1999-06-29 Application filed by Searle & Co filed Critical Searle & Co

2004-11-10 Publication of OA11629A publication Critical patent/OA11629A/en

Links

NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical class S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 title abstract description 23
239000003613 bile acid Substances 0.000 title abstract description 23
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract description 14
239000003112 inhibitor Substances 0.000 title abstract description 8
230000000694 effects Effects 0.000 title abstract description 7
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 title abstract 2
238000000034 method Methods 0.000 claims abstract description 77
125000000623 heterocyclic group Chemical group 0.000 claims description 453
125000000217 alkyl group Chemical group 0.000 claims description 403
125000003118 aryl group Chemical group 0.000 claims description 298
125000003342 alkenyl group Chemical group 0.000 claims description 293
125000000304 alkynyl group Chemical group 0.000 claims description 291
125000000753 cycloalkyl group Chemical group 0.000 claims description 267
125000003710 aryl alkyl group Chemical group 0.000 claims description 231
125000001072 heteroaryl group Chemical group 0.000 claims description 230
150000001875 compounds Chemical class 0.000 claims description 194
-1 ammoniumalkyl Chemical group 0.000 claims description 158
239000004721 Polyphenylene oxide Substances 0.000 claims description 145
229910052739 hydrogen Inorganic materials 0.000 claims description 145
229920000570 polyether Polymers 0.000 claims description 145
108090000765 processed proteins & peptides Proteins 0.000 claims description 138
229910052736 halogen Inorganic materials 0.000 claims description 133
150000002367 halogens Chemical class 0.000 claims description 133
125000001188 haloalkyl group Chemical group 0.000 claims description 132
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 107
125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 104
125000001424 substituent group Chemical group 0.000 claims description 89
125000004043 oxo group Chemical group O=* 0.000 claims description 87
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 81
239000001257 hydrogen Substances 0.000 claims description 78
150000001413 amino acids Chemical class 0.000 claims description 75
125000004181 carboxyalkyl group Chemical group 0.000 claims description 72
239000000203 mixture Substances 0.000 claims description 72
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 72
235000001014 amino acid Nutrition 0.000 claims description 69
229920001184 polypeptide Polymers 0.000 claims description 68
102000004196 processed proteins & peptides Human genes 0.000 claims description 68
229910052760 oxygen Inorganic materials 0.000 claims description 63
150000001720 carbohydrates Chemical class 0.000 claims description 62
125000003545 alkoxy group Chemical group 0.000 claims description 59
125000004122 cyclic group Chemical group 0.000 claims description 58
230000008569 process Effects 0.000 claims description 58
229910052757 nitrogen Inorganic materials 0.000 claims description 57
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 54
125000002252 acyl group Chemical group 0.000 claims description 52
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 52
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 52
239000003795 chemical substances by application Substances 0.000 claims description 51
125000002877 alkyl aryl group Chemical group 0.000 claims description 47
229910052799 carbon Inorganic materials 0.000 claims description 45
125000004423 acyloxy group Chemical group 0.000 claims description 41
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 39
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 38
125000004433 nitrogen atom Chemical group N* 0.000 claims description 34
125000004948 alkyl aryl alkyl group Chemical group 0.000 claims description 31
125000004414 alkyl thio group Chemical group 0.000 claims description 31
125000004663 dialkyl amino group Chemical group 0.000 claims description 31
125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 30
150000003839 salts Chemical group 0.000 claims description 30
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 26
150000001768 cations Chemical class 0.000 claims description 26
150000002431 hydrogen Chemical class 0.000 claims description 25
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 23
150000001450 anions Chemical class 0.000 claims description 23
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
125000004964 sulfoalkyl group Chemical group 0.000 claims description 21
150000005171 halobenzenes Chemical class 0.000 claims description 19
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 17
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 16
229910000104 sodium hydride Inorganic materials 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 16
101150020251 NR13 gene Proteins 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 15
239000002585 base Substances 0.000 claims description 15
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 14
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 claims description 14
125000004946 alkenylalkyl group Chemical group 0.000 claims description 13
125000005038 alkynylalkyl group Chemical group 0.000 claims description 13
125000004966 cyanoalkyl group Chemical group 0.000 claims description 13
125000002950 monocyclic group Chemical group 0.000 claims description 13
125000003367 polycyclic group Chemical group 0.000 claims description 13
239000012312 sodium hydride Substances 0.000 claims description 13
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 12
101100379081 Emericella variicolor andC gene Proteins 0.000 claims description 11
150000001721 carbon Chemical group 0.000 claims description 11
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 11
239000007800 oxidant agent Substances 0.000 claims description 10
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 9
239000002552 dosage form Substances 0.000 claims description 8
239000000651 prodrug Substances 0.000 claims description 8
229940002612 prodrug Drugs 0.000 claims description 8
102220465932 Beta-1,3-glucuronyltransferase LARGE2_R13A_mutation Human genes 0.000 claims description 7
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 7
125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 7
125000004429 atom Chemical group 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
GLNWILHOFOBOFD-UHFFFAOYSA-N lithium sulfide Chemical group [Li+].[Li+].[S-2] GLNWILHOFOBOFD-UHFFFAOYSA-N 0.000 claims description 5
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 5
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 4
239000003513 alkali Substances 0.000 claims description 4
125000001309 chloro group Chemical group Cl* 0.000 claims description 4
230000001590 oxidative effect Effects 0.000 claims description 4
150000003457 sulfones Chemical class 0.000 claims description 4
HCUOEKSZWPGJIM-YBRHCDHNSA-N (e,2e)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 claims description 3
101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 claims description 3
101000598778 Homo sapiens Protein OSCP1 Proteins 0.000 claims description 3
208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
101001067395 Mus musculus Phospholipid scramblase 1 Proteins 0.000 claims description 3
102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 claims description 3
150000004703 alkoxides Chemical class 0.000 claims description 3
125000003282 alkyl amino group Chemical group 0.000 claims description 3
150000004678 hydrides Chemical class 0.000 claims description 2
125000001544 thienyl group Chemical group 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 6
101150064767 NNR1 gene Proteins 0.000 claims 3
230000008878 coupling Effects 0.000 claims 2
238000010168 coupling process Methods 0.000 claims 2
238000005859 coupling reaction Methods 0.000 claims 2
125000006575 electron-withdrawing group Chemical group 0.000 claims 2
229910006074 SO2NH2 Inorganic materials 0.000 claims 1
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
230000003143 atherosclerotic effect Effects 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 90
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
239000000243 solution Substances 0.000 description 78
YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 68
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
238000006243 chemical reaction Methods 0.000 description 54
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 47
229910001868 water Inorganic materials 0.000 description 47
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 46
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 36
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
239000000047 product Substances 0.000 description 34
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
238000003756 stirring Methods 0.000 description 30
235000014633 carbohydrates Nutrition 0.000 description 29
235000019439 ethyl acetate Nutrition 0.000 description 28
229940093499 ethyl acetate Drugs 0.000 description 28
239000003921 oil Substances 0.000 description 27
150000003254 radicals Chemical group 0.000 description 27
235000019198 oils Nutrition 0.000 description 26
238000005481 NMR spectroscopy Methods 0.000 description 25
238000007792 addition Methods 0.000 description 24
239000012044 organic layer Substances 0.000 description 24
229910052943 magnesium sulfate Inorganic materials 0.000 description 23
235000019341 magnesium sulphate Nutrition 0.000 description 23
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
229940073584 methylene chloride Drugs 0.000 description 22
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
238000001819 mass spectrum Methods 0.000 description 21
238000010992 reflux Methods 0.000 description 20
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
239000010410 layer Substances 0.000 description 18
229940035423 ethyl ether Drugs 0.000 description 16
239000011541 reaction mixture Substances 0.000 description 16
239000007789 gas Substances 0.000 description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
235000011121 sodium hydroxide Nutrition 0.000 description 15
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
239000007787 solid Substances 0.000 description 14
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 12
239000012267 brine Substances 0.000 description 12
125000004432 carbon atom Chemical group C* 0.000 description 12
239000000284 extract Substances 0.000 description 12
235000011118 potassium hydroxide Nutrition 0.000 description 12
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 12
238000000746 purification Methods 0.000 description 12
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
201000010099 disease Diseases 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
238000010926 purge Methods 0.000 description 11
JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 10
238000004949 mass spectrometry Methods 0.000 description 10
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
229910052717 sulfur Inorganic materials 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 9
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
230000037396 body weight Effects 0.000 description 9
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
235000002568 Capsicum frutescens Nutrition 0.000 description 8
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 8
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 8
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
239000002904 solvent Substances 0.000 description 8
239000007858 starting material Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 8
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 8
239000003643 water by type Substances 0.000 description 8
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
201000001320 Atherosclerosis Diseases 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
239000000543 intermediate Substances 0.000 description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
238000004809 thin layer chromatography Methods 0.000 description 7
229940099408 Oxidizing agent Drugs 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
150000001335 aliphatic alkanes Chemical class 0.000 description 6
150000001345 alkine derivatives Chemical class 0.000 description 6
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
125000005842 heteroatom Chemical group 0.000 description 6
230000003647 oxidation Effects 0.000 description 6
238000007254 oxidation reaction Methods 0.000 description 6
239000012071 phase Substances 0.000 description 6
229940093932 potassium hydroxide Drugs 0.000 description 6
238000010898 silica gel chromatography Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
229940083608 sodium hydroxide Drugs 0.000 description 6
229910021653 sulphate ion Inorganic materials 0.000 description 6
239000000725 suspension Substances 0.000 description 6
241000124008 Mammalia Species 0.000 description 5
XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 5
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
150000001336 alkenes Chemical class 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
239000002775 capsule Substances 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
125000005843 halogen group Chemical group 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 5
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
GDVUGFJXFFCXMX-UHFFFAOYSA-N (2-ethyl-2-formylhexyl) methanesulfonate Chemical compound CCCCC(CC)(C=O)COS(C)(=O)=O GDVUGFJXFFCXMX-UHFFFAOYSA-N 0.000 description 4
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
229940077672 Ileal bile acid transport inhibitor Drugs 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
238000001816 cooling Methods 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000000605 extraction Methods 0.000 description 4
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
125000004585 polycyclic heterocycle group Chemical group 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
235000015320 potassium carbonate Nutrition 0.000 description 4
230000035484 reaction time Effects 0.000 description 4
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
229910001220 stainless steel Inorganic materials 0.000 description 4
239000010935 stainless steel Substances 0.000 description 4
AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical group O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 4
238000005406 washing Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
229920001268 Cholestyramine Polymers 0.000 description 3
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
102000007330 LDL Lipoproteins Human genes 0.000 description 3
108010007622 LDL Lipoproteins Proteins 0.000 description 3
229910001216 Li2S Inorganic materials 0.000 description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
125000005605 benzo group Chemical group 0.000 description 3
210000000941 bile Anatomy 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
235000008504 concentrate Nutrition 0.000 description 3
239000012043 crude product Substances 0.000 description 3
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000010235 enterohepatic circulation Effects 0.000 description 3
238000004817 gas chromatography Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000005227 gel permeation chromatography Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000003301 hydrolyzing effect Effects 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
125000002911 monocyclic heterocycle group Chemical group 0.000 description 3
PHWISQNXPLXQRU-UHFFFAOYSA-N n,n-dimethylcarbamothioyl chloride Chemical compound CN(C)C(Cl)=S PHWISQNXPLXQRU-UHFFFAOYSA-N 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
125000001453 quaternary ammonium group Chemical group 0.000 description 3
238000010791 quenching Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
235000010265 sodium sulphite Nutrition 0.000 description 3
241000894007 species Species 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
229930192474 thiophene Natural products 0.000 description 3
238000012546 transfer Methods 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
125000005208 trialkylammonium group Chemical group 0.000 description 3
229940086542 triethylamine Drugs 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
VGISFWWEOGVMED-UHFFFAOYSA-N 1-(chloromethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CCl)=C1 VGISFWWEOGVMED-UHFFFAOYSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
HKQWVTWXDVJYOD-UHFFFAOYSA-N 2-[(2-benzoylphenyl)sulfanylmethyl]-2-ethylhexanal Chemical compound CCCCC(CC)(C=O)CSC1=CC=CC=C1C(=O)C1=CC=CC=C1 HKQWVTWXDVJYOD-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 2
YHHNADPSYJLFOC-UHFFFAOYSA-N 4-fluoro-2-[(3-methoxyphenyl)methyl]benzenethiol Chemical compound COC1=CC=CC(CC=2C(=CC=C(F)C=2)S)=C1 YHHNADPSYJLFOC-UHFFFAOYSA-N 0.000 description 2
BVPBZMRUHRLQGE-UHFFFAOYSA-N 4-fluoro-2-[(3-methoxyphenyl)methyl]phenol Chemical compound COC1=CC=CC(CC=2C(=CC=C(F)C=2)O)=C1 BVPBZMRUHRLQGE-UHFFFAOYSA-N 0.000 description 2
RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
241000220479 Acacia Species 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000000853 LDL receptors Human genes 0.000 description 2
108010001831 LDL receptors Proteins 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
BUIQRTDBPCHRIR-UHFFFAOYSA-L O[Cr](Cl)(=O)=O Chemical compound O[Cr](Cl)(=O)=O BUIQRTDBPCHRIR-UHFFFAOYSA-L 0.000 description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
239000006286 aqueous extract Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical group [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
229960004132 diethyl ether Drugs 0.000 description 2
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
239000012259 ether extract Substances 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
125000004705 ethylthio group Chemical group C(C)S* 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
FKNQCJSGGFJEIZ-UHFFFAOYSA-N gamma-methylpyridine Natural products CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
150000002460 imidazoles Chemical class 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
239000013067 intermediate product Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
125000002346 iodo group Chemical group I* 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229960001047 methyl salicylate Drugs 0.000 description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
239000012452 mother liquor Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
239000003444 phase transfer catalyst Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000006187 pill Substances 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
125000000168 pyrrolyl group Chemical group 0.000 description 2
150000003242 quaternary ammonium salts Chemical class 0.000 description 2
238000011160 research Methods 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
238000007493 shaping process Methods 0.000 description 2
239000002002 slurry Substances 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
235000011149 sulphuric acid Nutrition 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
125000001425 triazolyl group Chemical group 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
238000010792 warming Methods 0.000 description 2
UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
IOWGHQGLUMEZKG-UHFFFAOYSA-N (2-bromophenyl)methanol Chemical compound OCC1=CC=CC=C1Br IOWGHQGLUMEZKG-UHFFFAOYSA-N 0.000 description 1
PGIPTXFXNUVZFZ-UHFFFAOYSA-N (2-chloro-4-nitrophenyl)-phenylmethanone Chemical compound ClC1=CC([N+](=O)[O-])=CC=C1C(=O)C1=CC=CC=C1 PGIPTXFXNUVZFZ-UHFFFAOYSA-N 0.000 description 1
HRPHZUAPQWJPCZ-UHFFFAOYSA-N (2-chloro-5-nitrophenyl)-phenylmethanone Chemical compound [O-][N+](=O)C1=CC=C(Cl)C(C(=O)C=2C=CC=CC=2)=C1 HRPHZUAPQWJPCZ-UHFFFAOYSA-N 0.000 description 1
FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LSXZSLZITPNDSA-UHFFFAOYSA-N 1$l^{6}-benzothiepine 1,1-dioxide Chemical class O=S1(=O)C=CC=CC2=CC=CC=C12 LSXZSLZITPNDSA-UHFFFAOYSA-N 0.000 description 1
BCAGFJXMCZSAHD-UHFFFAOYSA-N 1,2-bis(2-iodoethoxy)ethane Chemical compound ICCOCCOCCI BCAGFJXMCZSAHD-UHFFFAOYSA-N 0.000 description 1
LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
IUKHPYXSMWHAJG-UHFFFAOYSA-N 2,3-dihydro-1-benzothiepine Chemical compound S1CCC=CC2=CC=CC=C21 IUKHPYXSMWHAJG-UHFFFAOYSA-N 0.000 description 1
RLRUKKDFNWXXRT-UHFFFAOYSA-N 2,5-difluorobenzoyl chloride Chemical compound FC1=CC=C(F)C(C(Cl)=O)=C1 RLRUKKDFNWXXRT-UHFFFAOYSA-N 0.000 description 1
RCQMOSJJIVCPJO-UHFFFAOYSA-N 2-(5-methyl-2,4-dioxopyrimidin-1-yl)ethoxymethylphosphonic acid Chemical compound CC1=CN(CCOCP(O)(O)=O)C(=O)NC1=O RCQMOSJJIVCPJO-UHFFFAOYSA-N 0.000 description 1
UVEFAZXHHJHMGK-UHFFFAOYSA-N 2-ethyl-2-(hydroxymethyl)hexanal Chemical compound CCCCC(CC)(CO)C=O UVEFAZXHHJHMGK-UHFFFAOYSA-N 0.000 description 1
ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical class FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
OIOASXNVXSNIKG-UHFFFAOYSA-N 2-iodoethyl hypoiodite Chemical compound ICCOI OIOASXNVXSNIKG-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QUEKGYQTRJVEQC-UHFFFAOYSA-N 2516-96-3 Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1Cl QUEKGYQTRJVEQC-UHFFFAOYSA-N 0.000 description 1
BSTJYEHXNQXLSR-UHFFFAOYSA-N 3,5-dibutyl-4-fluorophthalaldehyde Chemical compound CCCCC1=CC(C=O)=C(C=O)C(CCCC)=C1F BSTJYEHXNQXLSR-UHFFFAOYSA-N 0.000 description 1
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
ZNRGSYUVFVNSAW-UHFFFAOYSA-N 3-nitrophenylboronic acid Chemical compound OB(O)C1=CC=CC([N+]([O-])=O)=C1 ZNRGSYUVFVNSAW-UHFFFAOYSA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
OKRUMSWHDWKGHA-UHFFFAOYSA-N 5-bromopentanoyl chloride Chemical compound ClC(=O)CCCCBr OKRUMSWHDWKGHA-UHFFFAOYSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
241000070928 Calligonum comosum Species 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
KBXILIYZUWEKCM-UHFFFAOYSA-N N-amino-N-ethylsulfanylhydroxylamine Chemical compound CCSN(N)O KBXILIYZUWEKCM-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
229910006069 SO3H Inorganic materials 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
ZDVDCDLBOLSVGM-UHFFFAOYSA-N [chloro(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(Cl)C1=CC=CC=C1 ZDVDCDLBOLSVGM-UHFFFAOYSA-N 0.000 description 1
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000003705 anilinocarbonyl group Chemical group O=C([*])N([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
239000003529 anticholesteremic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
150000005840 aryl radicals Chemical group 0.000 description 1
125000000732 arylene group Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
LCMRBQHJXNAKQR-UHFFFAOYSA-N benzenethiol;benzylbenzene Chemical compound SC1=CC=CC=C1.C=1C=CC=CC=1CC1=CC=CC=C1 LCMRBQHJXNAKQR-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
239000012965 benzophenone Substances 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000035587 bioadhesion Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
BPVYMDMPLCOQPJ-UHFFFAOYSA-L bis(trifluoromethylsulfonyloxy)mercury Chemical compound [Hg+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F BPVYMDMPLCOQPJ-UHFFFAOYSA-L 0.000 description 1
230000036765 blood level Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229910052681 coesite Inorganic materials 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000006071 cream Substances 0.000 description 1
229910052906 cristobalite Inorganic materials 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
238000007865 diluting Methods 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
230000004129 fatty acid metabolism Effects 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
208000001130 gallstones Diseases 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
125000004440 haloalkylsulfinyl group Chemical group 0.000 description 1
125000004995 haloalkylthio group Chemical group 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
125000000592 heterocycloalkyl group Chemical group 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
238000004896 high resolution mass spectrometry Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
229910000103 lithium hydride Inorganic materials 0.000 description 1
229940006116 lithium hydroxide Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
OHZZTXYKLXZFSZ-UHFFFAOYSA-I manganese(3+) 5,10,15-tris(1-methylpyridin-1-ium-4-yl)-20-(1-methylpyridin-4-ylidene)porphyrin-22-ide pentachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3].C1=CN(C)C=CC1=C1C(C=C2)=NC2=C(C=2C=C[N+](C)=CC=2)C([N-]2)=CC=C2C(C=2C=C[N+](C)=CC=2)=C(C=C2)N=C2C(C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 OHZZTXYKLXZFSZ-UHFFFAOYSA-I 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000005395 methacrylic acid group Chemical group 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
239000004533 oil dispersion Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229960002969 oleic acid Drugs 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
150000002924 oxiranes Chemical class 0.000 description 1
125000005702 oxyalkylene group Chemical group 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000008068 pathophysiological alteration Effects 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
125000005981 pentynyl group Chemical group 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
SPEXCGKGVJUPGG-UHFFFAOYSA-N phenyl-(2-sulfanylphenyl)methanone Chemical compound SC1=CC=CC=C1C(=O)C1=CC=CC=C1 SPEXCGKGVJUPGG-UHFFFAOYSA-N 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
229960005235 piperonyl butoxide Drugs 0.000 description 1
125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
235000020004 porter Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
229910000105 potassium hydride Inorganic materials 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
208000000876 primary bile acid malabsorption Diseases 0.000 description 1
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
125000003003 spiro group Chemical group 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229910052682 stishovite Inorganic materials 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
125000005504 styryl group Chemical group 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
125000001174 sulfone group Chemical group 0.000 description 1
125000000542 sulfonic acid group Chemical group 0.000 description 1
UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229910052905 tridymite Inorganic materials 0.000 description 1
125000004385 trihaloalkyl group Chemical group 0.000 description 1
CURCMGVZNYCRNY-UHFFFAOYSA-N trimethylazanium;iodide Chemical compound I.CN(C)C CURCMGVZNYCRNY-UHFFFAOYSA-N 0.000 description 1
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
150000004043 trisaccharides Chemical class 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655381—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a seven-(or more) membered ring
- C07F9/65539—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a seven-(or more) membered ring condensed with carbocyclic rings or carbocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Polymers & Plastics (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA1200000365A 1998-07-02 1999-06-29 Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake. OA11629A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/109,551 US5994391A (en)	1994-09-13	1998-07-02	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake

Publications (1)

Publication Number	Publication Date
OA11629A true OA11629A (en)	2004-11-10

Family

ID=22328263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000365A OA11629A (en)	1998-07-02	1999-06-29	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake.

Country Status (37)

Country	Link
US (1)	US5994391A (de)
EP (2)	EP1466911A3 (de)
JP (3)	JP2002519418A (de)
KR (1)	KR20010083084A (de)
CN (1)	CN1312805A (de)
AP (1)	AP2001002062A0 (de)
AR (1)	AR019880A1 (de)
AT (1)	ATE256122T1 (de)
AU (2)	AU766957B2 (de)
BG (1)	BG105206A (de)
BR (1)	BR9911737A (de)
CA (1)	CA2336315A1 (de)
CO (2)	CO4950537A1 (de)
DE (1)	DE69913530T2 (de)
DK (1)	DK1091953T3 (de)
EA (2)	EA200400149A1 (de)
EE (1)	EE200100002A (de)
ES (1)	ES2213373T3 (de)
GE (1)	GEP20032925B (de)
HK (1)	HK1039614A1 (de)
HR (1)	HRP20010004A2 (de)
HU (1)	HUP0102840A2 (de)
ID (1)	ID28221A (de)
IL (1)	IL140576A0 (de)
IS (1)	IS5798A (de)
NO (1)	NO20010016L (de)
NZ (1)	NZ509621A (de)
OA (1)	OA11629A (de)
PL (1)	PL346324A1 (de)
PT (1)	PT1091953E (de)
SG (1)	SG108309A1 (de)
SK (1)	SK20302000A3 (de)
TR (1)	TR200100824T2 (de)
TW (1)	TWI229670B (de)
WO (1)	WO2000001687A1 (de)
YU (1)	YU84400A (de)
ZA (1)	ZA200100028B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) *	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en)	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
BR9814300A (pt) *	1997-12-19	2002-02-05	Searle & Co	Método de preparação de óxidos de tetraidrobenzotiepina enanciomericamente enriquecidos
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) *	1998-06-10	2000-08-24	Aventis Pharma Gmbh	1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1140896A1 (de) *	1998-12-21	2001-10-10	Takeda Chemical Industries, Ltd.	Benzothiepin-anilid derivate, ihre herstellung und ihre verwendung als ccr-5 antagonisten
US6458850B1 (en) *	1998-12-23	2002-10-01	G.D. Searle, Llc	Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
AU3103800A (en) *	1998-12-23	2000-07-31	G.D. Searle Llc	Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
AU2157400A (en)	1998-12-23	2000-07-31	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
DK1140189T3 (da)	1998-12-23	2003-09-15	Searle Llc	Kombinationer af ileal galdesyre-transportinhibitorer og fibrinsyrederivater til cardiovaskulære indikationer
DE69911058T2 (de) *	1998-12-23	2004-06-03	G.D. Searle Llc, Chicago	Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
BR9916486A (pt)	1998-12-23	2002-02-05	Searle Llc	Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares
EA004877B1 (ru)	1998-12-23	2004-08-26	Джи.Ди.Сирл Ллс	Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
AU2157500A (en)	1998-12-23	2000-07-31	G.D. Searle Llc	Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
WO2000069845A1 (en) *	1999-05-18	2000-11-23	Takeda Chemical Industries, Ltd.	Processes for the preparation of 2,3-dihydrothiepine derivatives
SE0000772D0 (sv) *	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
EP1286984A2 (de) *	2000-03-10	2003-03-05	Pharmacia Corporation	Verfahren zur herstellung von tetrahydrobenzothiepinen
WO2001068096A2 (en) *	2000-03-10	2001-09-20	Pharmacia Corporation	Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6586474B2 (en)	2000-03-24	2003-07-01	Pharmacia Corporation	Amidino compounds useful as nitric oxide synthase inhibitors
US6787668B2 (en)	2000-04-13	2004-09-07	Pharmacia Corporation	2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
US6956131B2 (en)	2000-04-13	2005-10-18	Pharmacia Corporation	2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors
AR034120A1 (es)	2000-04-13	2004-02-04	Pharmacia Corp	Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
US6545170B2 (en)	2000-04-13	2003-04-08	Pharmacia Corporation	2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR032318A1 (es)	2000-04-13	2003-11-05	Pharmacia Corp	Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
AR030416A1 (es)	2000-04-13	2003-08-20	Pharmacia Corp	COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
JP2004512271A (ja)	2000-08-01	2004-04-22	ファルマシア・コーポレーション	誘導型一酸化窒素シンターゼ阻害薬としてのヘキサヒドロ−７−１ｈ−アゼピン−２−イル−ヘキサン酸誘導体
MY131964A (en)	2000-09-15	2007-09-28	Pharmacia Corp	2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AR031129A1 (es) *	2000-09-15	2003-09-10	Pharmacia Corp	Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
EG26979A (en)	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
IL156552A0 (en) *	2000-12-21	2004-01-04	Aventis Pharma Gmbh	Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
WO2002078625A2 (en) *	2001-03-28	2002-10-10	Pharmacia Corporation	Therapeutic combinations for cardiovascular and inflammatory indications
US20040077625A1 (en) *	2001-07-25	2004-04-22	Tremont Samuel J.	Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
MY131995A (en)	2001-09-08	2007-09-28	Astrazeneca Ab	Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
BR0212495A (pt) *	2001-09-12	2004-08-24	Searle Llc	Método para a preparação de tetraidrobenzotiepinas cristalinas
BR0213501A (pt) *	2001-11-02	2004-08-24	Searle Llc	Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
US20030112119A1 (en) *	2001-12-19	2003-06-19	Hom Wayne C.	Independent teleservicing module with a pager as its means of communication
MXPA04006255A (es)	2002-01-17	2004-09-27	Pharmacia Corp	Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
US20040014806A1 (en) *	2002-03-08	2004-01-22	Pharmacia Corporation	Methods and compositions for lowering levels of blood lipids
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en)	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
US7312208B2 (en)	2002-08-28	2007-12-25	Asahi Kasei Pharma Corporation	Quaternary ammonium compounds
WO2004020421A1 (ja) *	2002-08-28	2004-03-11	Asahi Kasei Pharma Corporation	新規な４級アンモニウム化合物
GB0304194D0 (en) *	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
WO2005042692A2 (en) *	2003-10-31	2005-05-12	Forbes Medi-Tech Inc.	A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
AU2005217318B2 (en)	2004-02-27	2010-07-01	Asahi Kasei Pharma Corporation	Novel benzothiazepine and benzothiepine compounds
DE102006053637B4 (de) *	2006-11-14	2011-06-30	Sanofi-Aventis Deutschland GmbH, 65929	Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102006053636B4 (de) *	2006-11-14	2008-09-18	Sanofi-Aventis Deutschland Gmbh	Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
ATE493992T1 (de) *	2006-11-14	2011-01-15	Sanofi Aventis Deutschland	Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102006053635B4 (de) *	2006-11-14	2011-06-30	Sanofi-Aventis Deutschland GmbH, 65929	Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102008022017A1 (de)	2008-05-02	2009-11-05	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von 1,4-Benzothiepin-1,1-Dioxidderivaten
US8461312B2 (en)	2008-05-02	2013-06-11	Sanofi	Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives
EP2367554A4 (de) *	2008-11-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Gallensäurerückflusshemmer zur behandlung von adipositas und diabetes
EP4137137A1 (de)	2010-05-26	2023-02-22	Satiogen Pharmaceuticals, Inc.	Gallensäurerecyclinghemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
MX366925B (es)	2010-11-04	2019-07-31	Albireo Ab	Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en)	2010-11-08	2013-09-12	Albireo Ab	Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
US20120114588A1 (en) *	2010-11-08	2012-05-10	Albireo Ab	Ibat inhibitors for treatment of metabolic disorders and related conditions
EA038594B1 (ru)	2011-10-28	2021-09-21	Шайр Хьюман Дженетик Терапис, Инк.	Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja)	2011-10-28	2017-10-25	ルメナファーマシューティカルズエルエルシー	小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
KR20160002773A (ko)	2013-03-15	2016-01-08	루메나 파마수티컬즈, 인코포레이티드	원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
AU2014229050A1 (en)	2013-03-15	2015-10-22	Lumena Pharmaceuticals Llc	Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar)	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en)	2014-06-25	2015-12-30	Ea Pharma Co., Ltd.	Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (de)	2014-10-24	2016-04-27	Ferring BV	Kristalline Form von elobixibat
RU2615769C2 (ru) *	2015-07-29	2017-04-11	Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Уфимский Государственный Университет Экономики И Сервиса"	Средство для ингибирования фермента альфа-амилазы
CN108601744B (zh)	2016-02-09	2022-01-04	阿尔比里奥公司	口服考来烯胺制剂及其用途
CA3011595C (en)	2016-02-09	2024-01-02	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
JP6954927B2 (ja)	2016-02-09	2021-10-27	アルビレオ・アクチボラグ	経口コレスチラミン製剤及びその使用
CN111032019B (zh)	2017-08-09	2022-07-05	阿尔比里奥公司	考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7328207B2 (ja)	2017-08-09	2023-08-16	アルビレオ・アクチボラグ	コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
JP7391048B2 (ja)	2018-06-05	2023-12-04	アルビレオ・アクチボラグ	ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
KR20210024033A (ko)	2018-06-20	2021-03-04	알비레오 에이비	오데빅시바트의 약학 제제
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
SG11202108566VA (en)	2019-02-06	2021-09-29	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
CN113453753B (zh)	2019-02-06	2024-07-23	阿尔比里奥公司	苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
EP4424363B1 (de)	2019-02-12	2026-04-29	Mirum Pharmaceuticals, Inc.	Verfahren zur wachstumssteigerung bei pädiatrischen patienten mit cholestatischer lebererkrankung
WO2021110885A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
JP7665621B2 (ja)	2019-12-04	2025-04-21	アルビレオ・アクチボラグ	ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3158181A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158195A1 (en)	2019-12-04	2021-06-10	Per-Goran Gillberg	Benzothia(di)azepine compounds and their use as bile acid modulators
CN114786772B (zh)	2019-12-04	2024-04-09	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
ES3002777T3 (en)	2020-08-03	2025-03-07	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
CN116157389B (zh) *	2020-08-03	2026-02-10	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AU2021379076A1 (en)	2020-11-12	2023-06-08	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt)	2020-12-04	2023-10-03	Albireo Ab	Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh)	2021-06-03	2024-01-16	阿尔比里奥公司	苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AU2023374724A1 (en)	2022-11-03	2025-05-01	Albireo Ab	Treating alagille syndrome (algs)
CN122094694A (zh)	2023-11-03	2026-05-26	阿尔比里奥公司	使用奥维昔巴特治疗pfic2

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3389144A (en) *	1965-06-08	1968-06-18	Mcneilab Inc	5-pyridyl-2, 3, 4, 5-tetrahydrobenzothiepin-5-ols
US3287370A (en) *	1965-06-08	1966-11-22	Mcneilab Inc	Tetrahydrobenzothiepins
DE1593760A1 (de) *	1967-02-01	1972-06-08	Boehringer Sohn Ingelheim	Verfahren zur Herstellung neuer Benz-epinderivate
US3444176A (en) *	1967-04-28	1969-05-13	Mcneilab Inc	Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof
US3694446A (en) *	1970-02-24	1972-09-26	William J Houlihan	5-(substituted-benzyl)-benzocycloheptenes and-1-benzthiepines
GB1428110A (en) *	1972-05-30	1976-03-17	Reckitt & Colmann Prod Ltd	Pharmaceutical antihypertensive and vasodilator compositions
US4207239A (en) *	1977-10-31	1980-06-10	The Upjohn Company	Benzothiepins
EP0304282A1 (de) *	1987-08-19	1989-02-22	E.I. Du Pont De Nemours And Company	Verfahren zur Herstellung von Sulfonylharnstoffsalzen
AU626881B2 (en) *	1988-07-14	1992-08-13	F. Hoffmann-La Roche Ag	Benzofused heterocyclics used as pharmaceuticals
DE3901527A1 (de) *	1989-01-20	1990-07-26	Hoechst Ag	Alkylierte polyethyleniminderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel sowie pharmazeutische praeparate
JPH0314576A (ja) *	1989-06-12	1991-01-23	Yoshitomi Pharmaceut Ind Ltd	１―ベンゾチエピン化合物
DE3930696A1 (de) *	1989-09-14	1991-03-28	Hoechst Ag	Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
FR2661676A1 (fr) *	1990-05-02	1991-11-08	Lipha	Derives d'amino benzocycloalcanes, procedes de preparation et medicaments les contenant.
JPH0825973B2 (ja) *	1991-04-12	1996-03-13	シェリング・コーポレーション	アシル補酵素ａ：コレステロールアシルトランスフェラーゼの阻害剤としての二環式アミド
EP0534316A1 (de) *	1991-09-21	1993-03-31	Hoechst Aktiengesellschaft	Verwendung von alkylierten Polyethyleniminderivaten zur Anreicherung von Gallensäuren
FI925734A7 (fi) *	1991-12-20	1993-06-21	Hoechst Ag	Polyaspartamidijohdoksia sappihapon adsorptioaineina, sappihappoja sisältäviä polyaspartamidijohdoksia ja menetelmä niiden valmistamiseksi sekä niiden käyttö lääkkeinä
NZ245504A (en) *	1991-12-20	1995-08-28	Hoechst Ag	Bile acid derivatives containing an ethylenically unsaturated grouping
FI108451B (fi) *	1991-12-20	2002-01-31	Hoechst Ag	Menetelmõ polymeeristen ja oligomeeristen sappihappojohdannaisten valmistamiseksi
GB9203347D0 (en) *	1992-02-17	1992-04-01	Wellcome Found	Hypolipidaemic compounds
DE59310171D1 (de) *	1992-02-29	2001-06-28	Aventis Res & Tech Gmbh & Co	Komplexe enthaltend Glykosyl-Phosphatidylinositol-Proteine und Cholansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE130193T1 (de) *	1992-03-28	1995-12-15	Hoechst Ag	Arzneimittel aus polyhydroxymethylenderivaten, verfahren zu deren herstellung und verwendung.
CA2093577C (en) *	1992-05-07	2006-01-03	Michael Klaus	Alkyl or alkoxy substituted s-heterocyclic retinoids
FR2698873B1 (fr) *	1992-12-07	1995-02-24	Lipha	Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.
IL108634A0 (en) *	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) *	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
TW289020B (de) *	1993-05-08	1996-10-21	Hoechst Sktiengesellschaft
TW289021B (de) *	1993-05-08	1996-10-21	Hoechst Ag
EP0624593A3 (de) *	1993-05-08	1995-06-07	Hoechst Ag	Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
US5491152A (en) *	1994-03-23	1996-02-13	The Du Pont Merck Pharmaceutical Company	Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
ZA956647B (en) *	1994-08-10	1997-02-10	Wellcome Found	Hypolipidaemic compounds.
ES2155136T3 (es) *	1994-09-13	2001-05-01	Monsanto Co	Nuevas benzotiepinas que tienen actividad como inhibidores del transporte de acido biliar iliaco y la captacion de taurocolato.
US5705524A (en) *	1994-11-04	1998-01-06	Gilead Sciences, Inc.	Thiepane compounds
GB9423172D0 (en) *	1994-11-17	1995-01-04	Wellcom Foundation The Limited	Hypolipidemic benzothiazepines
DE04010088T1 (de) *	1996-03-11	2005-07-14	G.D. Searle Llc	Neue Benzothiepine mit pharmazeutischer Wirkung.
NZ337830A (en) *	1997-03-11	2001-07-27	G	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5869528A (en) *	1997-07-22	1999-02-09	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Therapeutical method for the treatment of attention-deficit/hyperactive disorders
BR9814300A (pt) *	1997-12-19	2002-02-05	Searle & Co	Método de preparação de óxidos de tetraidrobenzotiepina enanciomericamente enriquecidos

1998
- 1998-07-02 US US09/109,551 patent/US5994391A/en not_active Expired - Fee Related
1999
- 1999-06-29 SK SK2030-2000A patent/SK20302000A3/sk unknown
- 1999-06-29 DK DK99931769T patent/DK1091953T3/da active
- 1999-06-29 PL PL99346324A patent/PL346324A1/xx unknown
- 1999-06-29 BR BR9911737-1A patent/BR9911737A/pt not_active IP Right Cessation
- 1999-06-29 ID IDW20010002A patent/ID28221A/id unknown
- 1999-06-29 WO PCT/US1999/012828 patent/WO2000001687A1/en not_active Ceased
- 1999-06-29 PT PT99931769T patent/PT1091953E/pt unknown
- 1999-06-29 NZ NZ509621A patent/NZ509621A/en unknown
- 1999-06-29 CA CA002336315A patent/CA2336315A1/en not_active Abandoned
- 1999-06-29 YU YU84400A patent/YU84400A/sh unknown
- 1999-06-29 HR HR20010004A patent/HRP20010004A2/hr not_active Application Discontinuation
- 1999-06-29 EA EA200400149A patent/EA200400149A1/ru unknown
- 1999-06-29 CN CN99809602A patent/CN1312805A/zh active Pending
- 1999-06-29 JP JP2000558091A patent/JP2002519418A/ja active Pending
- 1999-06-29 AT AT99931769T patent/ATE256122T1/de not_active IP Right Cessation
- 1999-06-29 GE GEAP19995707A patent/GEP20032925B/en unknown
- 1999-06-29 EP EP03026649A patent/EP1466911A3/de not_active Withdrawn
- 1999-06-29 EE EEP200100002A patent/EE200100002A/xx unknown
- 1999-06-29 ES ES99931769T patent/ES2213373T3/es not_active Expired - Lifetime
- 1999-06-29 TR TR2001/00824T patent/TR200100824T2/xx unknown
- 1999-06-29 HU HU0102840A patent/HUP0102840A2/hu unknown
- 1999-06-29 IL IL14057699A patent/IL140576A0/xx unknown
- 1999-06-29 SG SG200207701A patent/SG108309A1/en unknown
- 1999-06-29 KR KR1020017000027A patent/KR20010083084A/ko not_active Ceased
- 1999-06-29 OA OA1200000365A patent/OA11629A/en unknown
- 1999-06-29 EP EP99931769A patent/EP1091953B1/de not_active Expired - Lifetime
- 1999-06-29 EA EA200100002A patent/EA004650B1/ru not_active IP Right Cessation
- 1999-06-29 AP APAP/P/2001/002062A patent/AP2001002062A0/en unknown
- 1999-06-29 DE DE69913530T patent/DE69913530T2/de not_active Expired - Fee Related
- 1999-06-29 AU AU48202/99A patent/AU766957B2/en not_active Ceased
- 1999-06-29 HK HK02100948.1A patent/HK1039614A1/zh unknown
- 1999-07-02 AR ARP990103234A patent/AR019880A1/es unknown
- 1999-07-02 CO CO99041717A patent/CO4950537A1/es unknown
- 1999-07-02 CO CO99041717D patent/CO5080807A1/es unknown
2000
- 2000-01-07 TW TW088111293A patent/TWI229670B/zh not_active IP Right Cessation
- 2000-12-29 IS IS5798A patent/IS5798A/is unknown
2001
- 2001-01-02 NO NO20010016A patent/NO20010016L/no not_active Application Discontinuation
- 2001-01-02 ZA ZA200100028A patent/ZA200100028B/xx unknown
- 2001-01-31 BG BG105206A patent/BG105206A/bg unknown
2004
- 2004-01-30 AU AU2004200346A patent/AU2004200346A1/en not_active Abandoned
- 2004-02-25 JP JP2004050473A patent/JP2004203891A/ja active Pending
- 2004-08-03 JP JP2004227034A patent/JP2004359694A/ja active Pending

Also Published As

Publication number	Publication date
JP2002519418A (ja)	2002-07-02
HRP20010004A2 (en)	2001-12-31
SK20302000A3 (sk)	2001-11-06
YU84400A (sh)	2002-12-10
ID28221A (id)	2001-05-10
IS5798A (is)	2000-12-29
ATE256122T1 (de)	2003-12-15
NO20010016D0 (no)	2001-01-02
CO5080807A1 (es)	2001-09-25
HK1039614A1 (zh)	2002-05-03
TWI229670B (en)	2005-03-21
AP2001002062A0 (en)	2001-03-31
WO2000001687A1 (en)	2000-01-13
BG105206A (bg)	2001-09-28
CN1312805A (zh)	2001-09-12
ES2213373T3 (es)	2004-08-16
BR9911737A (pt)	2001-12-11
EA200100002A1 (ru)	2001-08-27
DE69913530T2 (de)	2004-09-23
EP1091953B1 (de)	2003-12-10
EA200400149A1 (ru)	2004-10-28
AU766957B2 (en)	2003-10-30
SG108309A1 (en)	2005-01-28
AR019880A1 (es)	2002-03-20
PT1091953E (pt)	2004-04-30
CA2336315A1 (en)	2000-01-13
US5994391A (en)	1999-11-30
EP1091953A1 (de)	2001-04-18
KR20010083084A (ko)	2001-08-31
JP2004203891A (ja)	2004-07-22
PL346324A1 (en)	2002-02-11
EE200100002A (et)	2002-06-17
ZA200100028B (en)	2001-07-25
EP1466911A3 (de)	2005-09-07
GEP20032925B (en)	2003-03-25
HUP0102840A2 (hu)	2002-01-28
EP1466911A2 (de)	2004-10-13
NZ509621A (en)	2003-08-29
NO20010016L (no)	2001-03-02
WO2000001687A9 (en)	2000-07-20
AU2004200346A1 (en)	2004-02-26
DK1091953T3 (da)	2004-04-13
CO4950537A1 (es)	2000-09-01
JP2004359694A (ja)	2004-12-24
DE69913530D1 (de)	2004-01-22
IL140576A0 (en)	2002-02-10
TR200100824T2 (tr)	2001-07-23
EA004650B1 (ru)	2004-06-24
AU4820299A (en)	2000-01-24

Publication	Publication Date	Title
EP1091953B1 (de)	2003-12-10	Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate-aufnahme
US6784201B2 (en)	2004-08-31	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
EP0888333B1 (de)	2005-08-31	Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate-aufnahme
US6642268B2 (en)	2003-11-04	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AU700557B2 (en)	1999-01-07	Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
WO1997033882A9 (en)	1998-02-26	Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CA2283575A1 (en)	1998-09-17	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
US6420417B1 (en)	2002-07-16	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
AU723123B2 (en)	2000-08-17	Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
MXPA01000208A (en)	2001-09-07	Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
EP1440972A1 (de)	2004-07-28	Neue Benzothiepine mit pharmazeutischer Wirkung.
HK1068342A (en)	2005-04-29	Novel benzothiepines having pharmaceutical activity
AU761249B2 (en)	2003-05-29	Novel intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CZ20004937A3 (cs)	2001-06-13	Benzothiepiny, které mají účinek jako inhibitory transportu žlučových kyselin v ileu a vychytávání taurocholátu